Intellia Therapeutics
NTLA
144 hedge funds and large institutions have $635M invested in Intellia Therapeutics in 2019 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 53 increasing their positions, 23 reducing their positions, and 21 closing their positions.
130% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 23
53% more call options, than puts
Call options by funds: $2.01M | Put options by funds: $1.32M
9.73% more ownership
Funds ownership: 75.19% → 84.92% (+9.7%)
9% more capital invested
Capital invested by funds: $582M → $635M (+$53.8M)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5% less first-time investments, than exits
New positions opened: 20 | Existing positions closed: 21
3% less funds holding
Funds holding: 148 → 144 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
+$64.3M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$18.4M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$5.84M |
| 4 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$4.12M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.88M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$16.9M |
| 2 |
OTPPB
Ontario Teachers' Pension Plan Board
Toronto,
Ontario, Canada
|
-$13.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$11.4M |
| 4 |
ROTUOC
Regents of the University of California
Oakland,
California
|
-$6.49M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.49M |
NTLA Hedge Fund Activity: Q2 2019 in Review
144 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q2 2019, worth a combined $635M — up 9.2% from $582M a quarter earlier.
Sellers outnumbered buyers: 21 funds closed out of NTLA and 20 opened new positions — a net loss of 1 holder — while 23 trimmed existing stakes and 53 added.
The largest buyer was Nikko Asset Management Americas, adding an estimated $64.3M. The largest seller was Morgan Stanley, cutting an estimated $16.9M.
- 144 institutional investors held Intellia Therapeutics (NTLA) as of Q2 2019, down from 148 in Q1 2019.
- Funds reported $635M of Intellia Therapeutics stock for Q2 2019, up 9.2% quarter-over-quarter.
- 20 funds opened new Intellia Therapeutics positions in Q2 2019 and 21 closed out, a net change of -1 holder.
- The largest Intellia Therapeutics buyer in Q2 2019 was Nikko Asset Management Americas, an estimated $64.3M added.
- The largest Intellia Therapeutics seller in Q2 2019 was Morgan Stanley, an estimated $16.9M sold.
Based on aggregated 13F filings for Q2 2019.